jopatclo wrote: GranhamB
the manipulative vulture who sold the shares of his family and friends at the end of 2020 at a loss sold it at .07 or .08? and now since this time want to buy at a low price. sad manipulative broker guy. GrahamB do you want me to deliver your message or do you say you want to buy at .12? GrahamB wrote:And yet after all these years. I have been correct- no sales, no China, no GE, no buyout, continued dilution, operating losses, and more promises and stories of waiting, waiting, wairing Fake GranhamB the manipulator here are the real facts Toronto, Ontario (May 1, 2024) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT; OTC:VPTDF) is pleased to announce that Duke University Health Center has
purchased its second VMS+ unit from Ventripoint , which processes ultrasound images of the
heart to generate MRI-quality measurements in minutes.
Duke Health Center Arringdon, part of the Duke University Health System located in Durham,
North Carolina. Duke Health, is affiliated with Duke University and is a world-class academic and
health care system.
“Tools that allow us to reduce the cost and time needed for reliable diagnostics can potentially
save the lives of infants, children and adults with heart conditions,” said Richard Krasuski, M.D.,
director of Duke’s Adult Congenital Heart Program.
Duke Children’s Hospital has been using Ventripoint’s VMS+ system for two years, focusing
primarily on single ventricle paediatric patients. Now, the VMS+ will be implemented at Duke
Cardiology Arringdon and will be used in real-time adult patient heart scans and help Duke further
its study of Ventripoint’s potential.
“We are very excited to work with Duke Cardiology Arringdon on our latest VMS+ system for their
cardiac clinic,” said Ventripoint Interim CEO, Hugh MacNaught. “We have had great success
working with Duke for their children’s health clinic, and we are sure that the Adult Congenital Heart
Disease program will also experience great results.”
Dear Friend;
I hope the summer break has been rejuvenating. The team at Ventripoint has been working hard to complete the next generation of the VMS+ product family and submit it for approval.
Here is some background:
1. VMS+3.0 is our current model, which is being used in hospitals in Canada, USA, Europe and UK. (VMS+2.0 is being manufactured and used in leading hospitals in China through a partnership).
2. VMS+4.0 is the next regeneration model which incorporates a number of novel measurements of heart function as well as novel ways to view the data in three dimensions. This newest version speeds up the analysis of the heart through AI-assisted point placements and automated view recognition. This makes the VMS+4.0 much easier to integrate into the standard workflow within an echocardiography service unit in a hospital, clinic or remote imaging center.
3. The company previously announced the submission to the US-FDA (see NR May 6, 2024).
4. Today we are announcing the submission to Health Canada, which was filed a few weeks ago (see attached NR). Health Canada typically responds more quickly than the US-FDA so expect this to move along quickly,
5. The Company is now preparing submissions for clearances in UK and EU (CE Mark).
6. The Company continues to engage existing users about the previously announced upgrade to VMS+3.2, which had an improved tracking component that did not have a magnet and so made the VMS+3.2 suitable for patients with ICDs like pacemakers and defibrillators. The upgrade also allows for rapid linkage and calibration to all existing 2D ultrasound devices sold by OEM manufacturers.
7. The Company will continue to sell the VMS+3.2 as the “standard" device and intends to sell the VMS+4.0 as a “premium" device at a premium price, once it has received regulatory clearances.
Thank you for your continued interest and support as we continue to improve heart diagnostics for everyone, everywhere and especially for children born with heart defects.
Regards,
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.